Maciej S.
- Country
- Poland
- Department
- Szpital Szamocka, Oddzial onkologii klinicznej/chemioterapii
Research Overview
- Evaluation of Safety and Antineoplastic Activity of OATD-02 in Patients with Advanced or Metastatic Solid Tumours: A Multicentre Rollover Study
- Phase 3 Randomized Study of Gedatolisib Combination Therapy versus Standard Endocrine Therapy in HR‑Positive, HER2‑Negative Advanced Breast Cancer Post‑CDK4/6 Inhibitor
- A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy
Data & Insights
Has run more than one trial at 33 of 165 partner sites.
Specializations
Oncology Research Focus
This investigator specializes in the treatment of advanced and metastatic solid tumors, with particular emphasis on multiple cancer types including colorectal cancer, ovarian cancer, pancreatic cancer, and renal cell carcinoma.
- Gynecological Oncology
- Gastrointestinal Oncology
- Urological Oncology
Breast Cancer Expertise
The investigator focuses on treating hormone receptor-positive and HER2-negative breast cancer, particularly in advanced stages. Their work includes research on patients who have undergone endocrine-based treatments.
- Metastatic Breast Cancer
- Hormone Receptor-Positive Disease
- Advanced Treatment Approaches
Novel Therapeutic Approaches
The investigator explores combination therapy approaches in treating various forms of cancer, with a particular interest in innovative treatment modalities for solid tumors.
- Combined Treatment Strategies
- Advanced Solid Tumors
- Therapeutic Innovation
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.